Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.38 |
| ▸ | TUBB | P07437 | 4/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.38 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.38 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19871227 | 0.78 | ALDH1A1 (0.35) | BRD4POLBKMT2AKDM4EALDH1A1 | |
| SCHEMBL30483746 | 0.73 | RHEB (0.41) | BRD4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10291045 | 0.73 | AHR (0.39) | POLBKMT2AKDM4EALDH1A1RHEB | |
| SCHEMBL12309702 | 0.73 | ADORA3 (0.41) | MEN1POLBKMT2AKDM4EALDH1A1 | |
| SCHEMBL6270065 | 0.73 | RHEB (0.41) | BRD4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL12786609 | 0.72 | ALDH1A1 (0.53) | TUBB1MEN1POLBMAPK1KMT2A | |
| SCHEMBL5567677 | 0.72 | BRD4 (0.53) | BRD4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL23640656 | 0.69 | ALDH1A1 (0.32) | POLBKMT2AKDM4EALDH1A1RHEB | |
| SCHEMBL19948493 | 0.69 | AHR (0.39) | POLBKMT2AKDM4EALDH1A1RHEB | |
| SCHEMBL1400405 | 0.69 | MTNR1A (0.47) | BRD4TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993616-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993616-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8829040-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829040-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20140179932-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140179932-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20130252955-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| US-20130252955-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| US-8466152-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2013-06-18 | — | — | US | disclosed |
| US-8466152-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20110230454-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230454-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-8003647-B2 | (Aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-8003647-B2 | (Aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | BRD4 3430/4885TUBB4A 4058/4885TUBB 3618/4885 |
| US-20140179932-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | BRD4 3430/4885TUBB4A 4058/4885TUBB 3618/4885 |
| US-20130252955-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | BRD4 3430/4885TUBB4A 4058/4885TUBB 3618/4885 |
| US-20110230454-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | BRD4 3430/4885TUBB4A 4058/4885TUBB 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.